search
Back to results

Efficacy of the Dietary Food Supplement ALCOFILTRUM in Alleviating Alcohol Hangover Symptoms

Primary Purpose

Alcohol Drinking, Alcohol Intoxication

Status
Recruiting
Phase
Not Applicable
Locations
Belarus
Study Type
Interventional
Intervention
ALCOFILTRUM
Sponsored by
AVVA Pharmaceuticals Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Alcohol Drinking

Eligibility Criteria

25 Years - 45 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria: Healthy men aged from 25 to 45 years inclusive. Body weight index of 18.5 to 30 kg/m2, with body weight of 60 kg to 100 kg. Healthy volunteers should behave adequately, with coherent speech observed. Available written Informed Consent for participation in this Study given by a healthy volunteer according to the effective laws. Subjects with history of episodic intake of alcohol and episodic hangover symptoms. Verified diagnosis "healthy": no chronic diseases in the history, no abnormal findings of lab tests and clinical investigations. Exclusion Criteria: The Investigator's decision that a healthy volunteer is to be excluded in the interests of the volunteer. Any serious adverse event occurring to a healthy volunteer and associated with intake of alcohol and/or the study product. A healthy volunteer refusing to collaborate with the Medical Investigator or not complying with the Study procedure. A healthy volunteer was enrolled into the Study with violation of the Clinical Study Protocol. Any adverse events occurring to a healthy volunteer that, in a Medical Investigator's opinion, may endanger safety of a volunteer. Positive urine opioid test. Positive COVID-19 Ag Rapid Test. Positive blood alcohol test judging by concentration of alcohol fumes in exhaled air. 0.15 mg/L or higher content of alcohol fumes in exhaled air at the Screening Visit and at Visits 2, 3 prior to intake the first alcohol portion.

Sites / Locations

  • Clinical Emergency HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

ALCOFILTRUM

Control

Arm Description

ALCOFILTRUM, 4 tablets in a single dose, 30 minutes prior to consumption of alcohol. Ingredients per tablet: Lignin hydrolyzed 800 mg; Glycine 150 mg; Dihydromyricetin 30 mg; Vitamin B1 30 mg.

Outcomes

Primary Outcome Measures

1-item overall hangover severity rating
Intensity of hangover symptoms in 12-13 hours after alcohol intake according to 1-item overall hangover severity rating. Score range is from 0 to 10, where higher scores mean more severe hangover symptoms.

Secondary Outcome Measures

Schulte test
Attention focusing and work efficiency according to Schulte test. Measurement timepoints: baseline, 1, 4, 12, 13 hours.
Romberg Stance test
Coordination and stability assessment in Romberg Stances. Measurement coordination and stability timepoints: baseline, 1, 4, 12, 13 hours.
Mini Cog test
Psychoneurological status. Measurement timepoints: baseline, 1, 4, 12, 13 hours.
Hangover Symptoms Questionnaire
Score of Hangover Symptoms Questionnaire and frequency of hangover symptoms. Score rating from 0 to 4 for 24 diferent symptoms, where higher scores mean higher severity of the symptoms. Measurement timepoints: baseline, 1, 4, 12, 13 hours.
Blood Alcohol level
Concentration of ethanol in per mille. Measurement timepoints: baseline, 1, 4, 12 hours.
Blood acetaldehyde level
Concentration of acetaldehyde in ng/mL. Measurement timepoints: baseline, 1, 4, 12 hours.
C-reactive protein level
Blood concentration of C-reactive protein in mg/L. Measurement timepoints: baseline, 4, 12 hours.
Bilirubin level
Blood concentrations of bilirubin and bilirubin fractions (direct and indirect) in umol/L. Measurement timepoints: baseline, 12 hours.
Blood Inflamatory markers
Concentrations of TNF-alpha and 8-isoprostane in pg/mL. Measurement timepoints: baseline, 4, 12 hours.
Liver enzyme markers
Blood concentrations of AST, ALT, ALP, GGT in u/L. Measurement timepoints: baseline, 12 hours.

Full Information

First Posted
January 12, 2023
Last Updated
March 3, 2023
Sponsor
AVVA Pharmaceuticals Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05757089
Brief Title
Efficacy of the Dietary Food Supplement ALCOFILTRUM in Alleviating Alcohol Hangover Symptoms
Official Title
An Open-label, Randomized, Cross-over, Comparative Study of ALCOFILTRUM Dietary Food Supplement for Alleviating Alcohol Hangover Symptoms in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 3, 2022 (Actual)
Primary Completion Date
March 30, 2023 (Anticipated)
Study Completion Date
May 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AVVA Pharmaceuticals Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this open-label, randomized, crossover, comparative pilot study is to assess efficacy and safety of the dietary food supplement ALCOFILTRUM in healthy volunteers who consume alcohol. Specifically the study will evaluate: Efficacy of the intervention to alleviate hangover symptoms in participants who consumed alcohol, Safety of intervention in participants who consuming alcohol. Participants will take four tablets of ALCOFILTRUM dietary food supplement 30 minutes before alcohol ingestion, while the control group will intake only alcohol drink.
Detailed Description
Heavy drinking of alcoholic beverages may lead to hangover, characterized by a combination of unpleasant physical and mental symptoms that affect mood, cognition, and physical functioning. Hangover symptoms begin within several hours following drinking cessation, when a person's blood alcohol concentration (BAC) is falling, and peak when BAC is zero. The symptoms may continue for up to 24 hours thereafter. Multiple contributing factors are responsible for the development of alcohol hangover symptoms which include ethanol itself, its metabolites and congeners / fusel alcohols. The liver plays a key role in alcohol detoxification, and is therefore affected the most. Drinking large amounts of alcohol can lead to significant damage to the liver and brain cells, the reason for the need for protection. In this open-label, randomized, cross-over, comparative pilot study investigators aim to assess efficacy and safety of the dietary food supplement ALCOFILTRUM in healthy volunteers who consume alcohol. Participants will consume an alcoholic drink (Bulbash Nano Original vodka 40%) in a dose calculated for every study subject based on ethanol 1.7g/kg body weight. The test group will take 4 tablets of ALCOFILTRUM dietary food supplement, 30 minutes before alcohol ingestion, while the control group will intake only alcohol drink. Twelve to thirteen hours after the last alcohol intake hangover symptoms will be evaluated based on questionnaires, and measurements of balance / coordination, attention and blood parameters. The findings from this study will provide important insight of a possible intervention for alleviating alcohol hangover symptoms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Drinking, Alcohol Intoxication

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ALCOFILTRUM
Arm Type
Experimental
Arm Description
ALCOFILTRUM, 4 tablets in a single dose, 30 minutes prior to consumption of alcohol. Ingredients per tablet: Lignin hydrolyzed 800 mg; Glycine 150 mg; Dihydromyricetin 30 mg; Vitamin B1 30 mg.
Arm Title
Control
Arm Type
No Intervention
Intervention Type
Dietary Supplement
Intervention Name(s)
ALCOFILTRUM
Intervention Description
ALCOFILTRUM helps alleviate alcohol hangover symptoms after a single intake for 30 minutes before alcohol consumption.
Primary Outcome Measure Information:
Title
1-item overall hangover severity rating
Description
Intensity of hangover symptoms in 12-13 hours after alcohol intake according to 1-item overall hangover severity rating. Score range is from 0 to 10, where higher scores mean more severe hangover symptoms.
Time Frame
13 hours
Secondary Outcome Measure Information:
Title
Schulte test
Description
Attention focusing and work efficiency according to Schulte test. Measurement timepoints: baseline, 1, 4, 12, 13 hours.
Time Frame
13 hours
Title
Romberg Stance test
Description
Coordination and stability assessment in Romberg Stances. Measurement coordination and stability timepoints: baseline, 1, 4, 12, 13 hours.
Time Frame
13 hours
Title
Mini Cog test
Description
Psychoneurological status. Measurement timepoints: baseline, 1, 4, 12, 13 hours.
Time Frame
13 hours
Title
Hangover Symptoms Questionnaire
Description
Score of Hangover Symptoms Questionnaire and frequency of hangover symptoms. Score rating from 0 to 4 for 24 diferent symptoms, where higher scores mean higher severity of the symptoms. Measurement timepoints: baseline, 1, 4, 12, 13 hours.
Time Frame
13 hours
Title
Blood Alcohol level
Description
Concentration of ethanol in per mille. Measurement timepoints: baseline, 1, 4, 12 hours.
Time Frame
12 hours
Title
Blood acetaldehyde level
Description
Concentration of acetaldehyde in ng/mL. Measurement timepoints: baseline, 1, 4, 12 hours.
Time Frame
12 hours
Title
C-reactive protein level
Description
Blood concentration of C-reactive protein in mg/L. Measurement timepoints: baseline, 4, 12 hours.
Time Frame
12 hours
Title
Bilirubin level
Description
Blood concentrations of bilirubin and bilirubin fractions (direct and indirect) in umol/L. Measurement timepoints: baseline, 12 hours.
Time Frame
12 hours
Title
Blood Inflamatory markers
Description
Concentrations of TNF-alpha and 8-isoprostane in pg/mL. Measurement timepoints: baseline, 4, 12 hours.
Time Frame
12 hours
Title
Liver enzyme markers
Description
Blood concentrations of AST, ALT, ALP, GGT in u/L. Measurement timepoints: baseline, 12 hours.
Time Frame
12 hours
Other Pre-specified Outcome Measures:
Title
Incidence of Adverse Events [Safety and Tolerability]
Description
Incidence rate of any adverse events.
Time Frame
5 days
Title
Incidence of Serious Adverse events [Safety and Tolerability]
Description
Incidence rate of any serious adverse events.
Time Frame
5 days
Title
Arterial blood pressure [Safety and Tolerability]
Description
Level of systolic and diastolic arterial blood pressure 1; 2; 3, 4, 12, 13 hours vs. baseline.
Time Frame
13 hours
Title
Heart rate [Safety and Tolerability]
Description
Hear rate 1; 2; 3, 4, 12, 13 hours vs. baseline.
Time Frame
13 hours

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy men aged from 25 to 45 years inclusive. Body weight index of 18.5 to 30 kg/m2, with body weight of 60 kg to 100 kg. Healthy volunteers should behave adequately, with coherent speech observed. Available written Informed Consent for participation in this Study given by a healthy volunteer according to the effective laws. Subjects with history of episodic intake of alcohol and episodic hangover symptoms. Verified diagnosis "healthy": no chronic diseases in the history, no abnormal findings of lab tests and clinical investigations. Exclusion Criteria: The Investigator's decision that a healthy volunteer is to be excluded in the interests of the volunteer. Any serious adverse event occurring to a healthy volunteer and associated with intake of alcohol and/or the study product. A healthy volunteer refusing to collaborate with the Medical Investigator or not complying with the Study procedure. A healthy volunteer was enrolled into the Study with violation of the Clinical Study Protocol. Any adverse events occurring to a healthy volunteer that, in a Medical Investigator's opinion, may endanger safety of a volunteer. Positive urine opioid test. Positive COVID-19 Ag Rapid Test. Positive blood alcohol test judging by concentration of alcohol fumes in exhaled air. 0.15 mg/L or higher content of alcohol fumes in exhaled air at the Screening Visit and at Visits 2, 3 prior to intake the first alcohol portion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Artemiy A. Sergeev, M.D., D.Sci.
Phone
+74952690016
Ext
3017
Email
sergeev@rnd.avvapharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olga A. Sharapova, Ph.D.
Organizational Affiliation
City Clinical Emergency Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Emergency Hospital
City
Minsk
ZIP/Postal Code
220024
Country
Belarus
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olga А. Sharapova, Ph.D.
Phone
+375172870001
Email
minsk.bsmp@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy of the Dietary Food Supplement ALCOFILTRUM in Alleviating Alcohol Hangover Symptoms

We'll reach out to this number within 24 hrs